Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Digital

Autores:: Schwartz, Gregory G.
Szarek, Michael
Bittner, Vera A.
Diaz, Rafael
Goodman, Shaun G.
Jukema, J. Wouter
Landmesser, Ulf
López-Jaramillo, Patricio
Manvelian, Garen
Pordy, Robert
Scemama, Michel
Sinnaeve, Peter R.
White, Harvey D.
Steg, Gabriel
ODYSSEY Outcomes Committees and Investigators

Tipo de recurso:: Article of journal

Fecha de publicación:: 2021

Institución:: Universidad de Santander

Repositorio:: Repositorio Universidad de Santander

Idioma:: eng

id	RUDES2_138e63eb064dc56cbe635e56107329ef
oai_identifier_str	oai:repositorio.udes.edu.co:001/6065
network_acronym_str	RUDES2
network_name_str	Repositorio Universidad de Santander
repository_id_str
dc.title.spa.fl_str_mv	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
title	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
spellingShingle	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol Acute coronary syndrome Lipoprotein(a) Low-density lipoprotein cholesterol PCSK9 inhibitor
title_short	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
title_full	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
title_fullStr	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
title_full_unstemmed	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
title_sort	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
dc.creator.fl_str_mv	Schwartz, Gregory G. Szarek, Michael Bittner, Vera A. Diaz, Rafael Goodman, Shaun G. Jukema, J. Wouter Landmesser, Ulf López-Jaramillo, Patricio Manvelian, Garen Pordy, Robert Scemama, Michel Sinnaeve, Peter R. White, Harvey D. Steg, Gabriel ODYSSEY Outcomes Committees and Investigators
dc.contributor.author.none.fl_str_mv	Schwartz, Gregory G. Szarek, Michael Bittner, Vera A. Diaz, Rafael Goodman, Shaun G. Jukema, J. Wouter Landmesser, Ulf López-Jaramillo, Patricio Manvelian, Garen Pordy, Robert Scemama, Michel Sinnaeve, Peter R. White, Harvey D. Steg, Gabriel ODYSSEY Outcomes Committees and Investigators
dc.contributor.researchgroup.spa.fl_str_mv	Masira
dc.subject.proposal.eng.fl_str_mv	Acute coronary syndrome Lipoprotein(a) Low-density lipoprotein cholesterol PCSK9 inhibitor
topic	Acute coronary syndrome Lipoprotein(a) Low-density lipoprotein cholesterol PCSK9 inhibitor
description	Digital
publishDate	2021
dc.date.issued.none.fl_str_mv	2021-08-03
dc.date.accessioned.none.fl_str_mv	2022-02-21T14:04:52Z
dc.date.available.none.fl_str_mv	2022-02-21T14:04:52Z
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv	Text
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.redcol.spa.fl_str_mv	http://purl.org/redcol/resource_type/ART
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.ark.none.fl_str_mv	https://doi.org/10.1016/j.jacc.2021.04.102
dc.identifier.uri.none.fl_str_mv	https://repositorio.udes.edu.co/handle/001/6065
url	https://doi.org/10.1016/j.jacc.2021.04.102 https://repositorio.udes.edu.co/handle/001/6065
dc.language.iso.spa.fl_str_mv	eng
language	eng
dc.relation.citationendpage.spa.fl_str_mv	433
dc.relation.citationissue.spa.fl_str_mv	5
dc.relation.citationstartpage.spa.fl_str_mv	421
dc.relation.citationvolume.spa.fl_str_mv	78
dc.relation.indexed.spa.fl_str_mv	Scopus
dc.relation.ispartofjournal.spa.fl_str_mv	Journal of the American College of Cardiology
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
dc.rights.creativecommons.spa.fl_str_mv	Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv	openAccess
rights_invalid_str_mv	Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_abf2
dc.format.extent.spa.fl_str_mv	13 p
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Elsevier
dc.publisher.place.spa.fl_str_mv	USA
dc.source.spa.fl_str_mv	https://www.sciencedirect.com/science/article/pii/S0735109721052475?via%3Dihub
institution	Universidad de Santander
bitstream.url.fl_str_mv	https://repositorio.udes.edu.co/bitstreams/3d225395-f4a0-4b4f-912e-d8922e034266/download https://repositorio.udes.edu.co/bitstreams/fb7d32b6-87d4-4089-9aac-972d51b3d30a/download https://repositorio.udes.edu.co/bitstreams/eb275252-0c94-4774-9305-edd649ce77b7/download https://repositorio.udes.edu.co/bitstreams/f9af28d1-7ef9-49b0-a38e-de17310ae33f/download
bitstream.checksum.fl_str_mv	019378d936c8be8c381b45b6f7257deb 38d94cf55aa1bf2dac1a736ac45c881c 5dbe86c1111d64f45ba435df98fdc825 49455d060d06b2b29d1bd2e0b2531f82
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5 MD5 MD5
repository.name.fl_str_mv	Repositorio Universidad de Santander
repository.mail.fl_str_mv	soporte@metabiblioteca.com
_version_	1814159020326387712
spelling	Schwartz, Gregory G.0b9e6dfc-0a1d-4287-aee3-7713fce86ece-1Szarek, Michaele170e054-026f-4b96-a3f9-bf538a71553f-1Bittner, Vera A.ab899d35-5158-4520-b79d-4e866540846e-1Diaz, Rafaelf2be4a74-501a-4e63-8bbd-965cbcf8c57b-1Goodman, Shaun G.7f7d25ba-48f2-4592-8b03-25be06199175-1Jukema, J. Woutere6ea1e4d-1059-465c-b34b-854ca0141a3e-1Landmesser, Ulfe2fd9c4a-a4e2-4cfa-82fe-82a9528084c3-1López-Jaramillo, Patriciof72eca20-6f41-45fe-a875-83c14605cb60-1Manvelian, Garen4313214f-cf48-4faa-a446-3961d8c5de48-1Pordy, Robertadb5a1bc-eeb7-4d31-bab1-bd073aa4d3e7-1Scemama, Michel6c3278cc-a589-4cc5-a2b1-d9ab678b83c4-1Sinnaeve, Peter R.f438e55b-0c51-485e-a6d4-9cbd6d9a6b03-1White, Harvey D.88cf0d68-0edb-4f0b-9457-53b047230cd0-1Steg, Gabriel5e15ab0e-e531-446a-8adf-a24611c97076-1ODYSSEY Outcomes Committees and Investigators18d1e891-7825-4987-8cab-b78c84a15489-1Masira2022-02-21T14:04:52Z2022-02-21T14:04:52Z2021-08-03DigitalBackground Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk. Objectives In a post hoc analysis of the ODYSSEY Outcomes (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, the authors evaluated the benefit of adding the proprotein subtilisin/kexin type 9 inhibitor alirocumab to optimized statin treatment in patients with LDL-C levels near 70 mg/dL. Effects were evaluated according to concurrent lipoprotein(a) levels. Methods ODYSSEY Outcomes compared alirocumab with placebo in 18,924 patients with recent acute coronary syndromes receiving optimized statin treatment. In 4,351 patients (23.0%), screening or randomization LDL-C was <70 mg/dL (median 69.4 mg/dL; interquartile range: 64.3-74.0 mg/dL); in 14,573 patients (77.0%), both determinations were ≥70 mg/dL (median 94.0 mg/dL; interquartile range: 83.2-111.0 mg/dL). Results In the lower LDL-C subgroup, MACE rates were 4.2 and 3.1 per 100 patient-years among placebo-treated patients with baseline lipoprotein(a) greater than or less than or equal to the median (13.7 mg/dL). Corresponding adjusted treatment hazard ratios were 0.68 (95% confidence interval [CI]: 0.52-0.90) and 1.11 (95% CI: 0.83-1.49), with treatment-lipoprotein(a) interaction on MACE (Pinteraction = 0.017). In the higher LDL-C subgroup, MACE rates were 4.7 and 3.8 per 100 patient-years among placebo-treated patients with lipoprotein(a) >13.7 mg/dL or ≤13.7 mg/dL; corresponding adjusted treatment hazard ratios were 0.82 (95% CI: 0.72-0.92) and 0.89 (95% CI: 0.75-1.06), with Pinteraction = 0.43. Conclusions In patients with recent acute coronary syndromes and LDL-C near 70 mg/dL on optimized statin therapy, proprotein subtilisin/kexin type 9 inhibition provides incremental clinical benefit only when lipoprotein(a) concentration is at least mildly elevated. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402)Ciencias Médicas y de la Salud13 papplication/pdfhttps://doi.org/10.1016/j.jacc.2021.04.102https://repositorio.udes.edu.co/handle/001/6065engElsevierUSA433542178ScopusJournal of the American College of Cardiology© 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.info:eu-repo/semantics/openAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_abf2https://www.sciencedirect.com/science/article/pii/S0735109721052475?via%3DihubAcute coronary syndromeLipoprotein(a)Low-density lipoprotein cholesterolPCSK9 inhibitorLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL CholesterolArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85Todas las AudienciasPublicationORIGINALLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.pdfLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.pdfapplication/pdf253228https://repositorio.udes.edu.co/bitstreams/3d225395-f4a0-4b4f-912e-d8922e034266/download019378d936c8be8c381b45b6f7257debMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-859https://repositorio.udes.edu.co/bitstreams/fb7d32b6-87d4-4089-9aac-972d51b3d30a/download38d94cf55aa1bf2dac1a736ac45c881cMD52TEXTLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.pdf.txtLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.pdf.txtExtracted texttext/plain5https://repositorio.udes.edu.co/bitstreams/eb275252-0c94-4774-9305-edd649ce77b7/download5dbe86c1111d64f45ba435df98fdc825MD53THUMBNAILLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.pdf.jpgLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.pdf.jpgGenerated Thumbnailimage/jpeg12240https://repositorio.udes.edu.co/bitstreams/f9af28d1-7ef9-49b0-a38e-de17310ae33f/download49455d060d06b2b29d1bd2e0b2531f82MD54001/6065oai:repositorio.udes.edu.co:001/60652023-10-09 16:53:24.719https://creativecommons.org/licenses/by-nc/4.0/© 2021 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.https://repositorio.udes.edu.coRepositorio Universidad de Santandersoporte@metabiblioteca.comTGljZW5jaWEgZGUgUHVibGljYWNpw7NuIFVERVMKRGlyZWN0cmljZXMgZGUgVVNPIHkgQUNDRVNPCgo=

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Publicaciones similares